Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

被引：108

作者：

FitzGerald, David J. ^{[1
]}

Wayne, Alan S. ^{[2
]}

Kreitman, Robert J. ^{[1
]}

Pastan, Ira ^{[1
]}

机构：

[1] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2011年 / 71卷 / 20期

关键词：

ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMAS; PHASE-II TRIAL; GEMTUZUMAB OZOGAMICIN; DENILEUKIN DIFTITOX; RFB4(DSFV)-PE38 BL22; CYTOTOXIC ACTIVITY; DIPHTHERIA IMMUNOTOXIN; PEDIATRIC-PATIENTS; CHAIN IMMUNOTOXIN;

D O I：

10.1158/0008-5472.CAN-11-1374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens. Cancer Res; 71( 20); 6300-9. (C) 2011 AACR.

引用

页码：6300 / 6309

页数：10

共 76 条

[1] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[2] Pre-clinical evaluation of the anti-CD22 immunotoxin CAT-8015 in combination with chemotherapy agents for childhood B-precursor acute lymphoblastic leukemia (pre-B ALL). [J].

Ahuja, Yachna ;

Stetler-Stevenson, Maryalice ;

Kreitman, Robert J. ;

Pastan, Ira ;

Wayne, Alan S. .

BLOOD, 2007, 110 (11) :265A-265A

[3] CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies [J].

Alderson, Ralph F. ;

Kreitman, Robert J. ;

Chen, Tianling ;

Yeung, Peter ;

Herbst, Ronald ;

Fox, Judy A. ;

Pastan, Ira .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :832-839

[4] Antibody-drug conjugates: targeted drug delivery for cancer [J].

Alley, Stephen C. ;

Okeley, Nicole M. ;

Senter, Peter D. .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537

[5]

AMLOT PL, 1993, BLOOD, V82, P2624

[6]

[Anonymous], ASH ANN M

[7]

[Anonymous], 2010, Blood, DOI DOI 10.1182/BLOOD.V116.21.3060.3060

[8]

[Anonymous], ASH ANN M

[9] Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: A report from the children's oncology group [J].

Aplenc, Richard ;

Alonzo, Todd A. ;

Gerbing, Robert B. ;

Lange, Beverly J. ;

Hurwitz, Craig A. ;

Wells, Robert J. ;

Bernstein, Irwin ;

Buckley, Patrick ;

Krimmel, Kathleen ;

Smith, Franklin O. ;

Sievers, Eric L. ;

Arceci, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2390-2395

[10] Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia [J].

Arceci, RJ ;

Sande, J ;

Lange, B ;

Shannon, K ;

Franklin, J ;

Hutchinson, R ;

Vik, TA ;

Flowers, D ;

Aplenc, R ;

Berger, MS ;

Sherman, ML ;

Smith, FO ;

Bernstein, I ;

Sievers, EL .

BLOOD, 2005, 106 (04) :1183-1188

← 1 2 3 4 5 6 7 8 →